Claudia Gandolfo

TL;DR: In this article, the BNT162b2 vaccine was evaluated in 100 health care workers, 38 of whom had recovered from Covid-19, and neutralizing antibody levels.

TL;DR: The results suggest that the mPEBev regimen improve the micro-environmental conditions for an efficient antigen-specific CTL response, making it a feasible candidate regimen to be assessed in combination with immune-checkpoint inhibitors in NSCLC patients.

TL;DR: In this article, the authors characterized the mechanism by which SARS-CoV-2 N counteracts INF-β secretion and affects RIG-I signaling pathways and found that when the N protein was ectopically expressed, there was a marked decrease in TRIM25-mediated RIGI activation.

TL;DR: Both treatment-modules showed immunomodulating and antitumor activity and the promising long-term survival produced by the sequential treatment module deserves further phase II evaluation.

TL;DR: The findings of this phase Ib trial provide the framework for the evaluation of the TSPP anti-tumor activity in further disease-oriented clinical trials.